These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

535 related articles for article (PubMed ID: 29741794)

  • 1. Targeting Bruton's tyrosine kinase for the treatment of B cell associated malignancies and autoimmune diseases: Preclinical and clinical developments of small molecule inhibitors.
    Zhang Z; Zhang D; Liu Y; Yang D; Ran F; Wang ML; Zhao G
    Arch Pharm (Weinheim); 2018 Jul; 351(7):e1700369. PubMed ID: 29741794
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting Bruton's Tyrosine Kinase Across B-Cell Malignancies.
    da Cunha-Bang C; Niemann CU
    Drugs; 2018 Nov; 78(16):1653-1663. PubMed ID: 30390220
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting Bruton's tyrosine kinase with ibrutinib in B-cell malignancies.
    Wang Y; Zhang LL; Champlin RE; Wang ML
    Clin Pharmacol Ther; 2015 May; 97(5):455-68. PubMed ID: 25669675
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acalabrutinib, A Second-Generation Bruton's Tyrosine Kinase Inhibitor.
    Kriegsmann K; Kriegsmann M; Witzens-Harig M
    Recent Results Cancer Res; 2018; 212():285-294. PubMed ID: 30069636
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting Bruton's tyrosine kinase in B cell malignancies.
    Hendriks RW; Yuvaraj S; Kil LP
    Nat Rev Cancer; 2014 Apr; 14(4):219-32. PubMed ID: 24658273
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bruton's tyrosine kinase: from X-linked agammaglobulinemia toward targeted therapy for B-cell malignancies.
    Ponader S; Burger JA
    J Clin Oncol; 2014 Jun; 32(17):1830-9. PubMed ID: 24778403
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of Bruton's tyrosine kinase in B cells and malignancies.
    Pal Singh S; Dammeijer F; Hendriks RW
    Mol Cancer; 2018 Feb; 17(1):57. PubMed ID: 29455639
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relative Selectivity of Covalent Inhibitors Requires Assessment of Inactivation Kinetics and Cellular Occupancy: A Case Study of Ibrutinib and Acalabrutinib.
    Hopper M; Gururaja T; Kinoshita T; Dean JP; Hill RJ; Mongan A
    J Pharmacol Exp Ther; 2020 Mar; 372(3):331-338. PubMed ID: 31871305
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy.
    Honigberg LA; Smith AM; Sirisawad M; Verner E; Loury D; Chang B; Li S; Pan Z; Thamm DH; Miller RA; Buggy JJ
    Proc Natl Acad Sci U S A; 2010 Jul; 107(29):13075-80. PubMed ID: 20615965
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bruton's tyrosine kinase inhibitors in B-cell non-Hodgkin's lymphomas.
    Alinari L; Quinion C; Blum KA
    Clin Pharmacol Ther; 2015 May; 97(5):469-77. PubMed ID: 25670208
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bruton Kinase Inhibitors in Chronic Lymphocytic Leukemia.
    Gozzetti A; Candi V; Brambilla CZ; Papini G; Fabbri A; Bocchia M
    Anticancer Agents Med Chem; 2017; 17(8):1040-1045. PubMed ID: 27697038
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibiting Bruton's Tyrosine Kinase in CLL and Other B-Cell Malignancies.
    Lucas F; Woyach JA
    Target Oncol; 2019 Apr; 14(2):125-138. PubMed ID: 30927175
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current Status of Bruton's Tyrosine Kinase Inhibitor Development and Use in B-Cell Malignancies.
    Aw A; Brown JR
    Drugs Aging; 2017 Jul; 34(7):509-527. PubMed ID: 28536906
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Irreversible dual inhibitory mode: the novel Btk inhibitor PLS-123 demonstrates promising anti-tumor activity in human B-cell lymphoma.
    Ding N; Li X; Shi Y; Ping L; Wu L; Fu K; Feng L; Zheng X; Song Y; Pan Z; Zhu J
    Oncotarget; 2015 Jun; 6(17):15122-36. PubMed ID: 25944695
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PCI-32765: a novel Bruton's tyrosine kinase inhibitor for the treatment of lymphoid malignancies.
    Winer ES; Ingham RR; Castillo JJ
    Expert Opin Investig Drugs; 2012 Mar; 21(3):355-61. PubMed ID: 22300471
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bruton's Tyrosine Kinase Inhibition Attenuates the Cardiac Dysfunction Caused by Cecal Ligation and Puncture in Mice.
    O'Riordan CE; Purvis GSD; Collotta D; Chiazza F; Wissuwa B; Al Zoubi S; Stiehler L; Martin L; Coldewey SM; Collino M; Thiemermann C
    Front Immunol; 2019; 10():2129. PubMed ID: 31552054
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dermatological Toxicities of Bruton's Tyrosine Kinase Inhibitors.
    Sibaud V; Beylot-Barry M; Protin C; Vigarios E; Recher C; Ysebaert L
    Am J Clin Dermatol; 2020 Dec; 21(6):799-812. PubMed ID: 32613545
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Bruton's tyrosine kinase inhibitor ibrutinib exerts immunomodulatory effects through regulation of tumor-infiltrating macrophages.
    Ping L; Ding N; Shi Y; Feng L; Li J; Liu Y; Lin Y; Shi C; Wang X; Pan Z; Song Y; Zhu J
    Oncotarget; 2017 Jun; 8(24):39218-39229. PubMed ID: 28424405
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tyrosine kinase inhibitors as potential drugs for B-cell lymphoid malignancies and autoimmune disorders.
    Robak T; Robak E
    Expert Opin Investig Drugs; 2012 Jul; 21(7):921-47. PubMed ID: 22612424
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimizing Platelet GPVI Inhibition versus Haemostatic Impairment by the Btk Inhibitors Ibrutinib, Acalabrutinib, ONO/GS-4059, BGB-3111 and Evobrutinib.
    Denzinger V; Busygina K; Jamasbi J; Pekrul I; Spannagl M; Weber C; Lorenz R; Siess W
    Thromb Haemost; 2019 Mar; 119(3):397-406. PubMed ID: 30685871
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.